Abstract

WITH A FEW EXCEPTIONS, earnings for pharmaceutical firms did not live up to investors' and each company's own expectations, both in the fourth quarter and for the full year. In addition to well-pub...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call